Abstract:The in vivo immunoregulatory effect of anergic cells induced by blocking the costimulatory pathway was investigated in this study. Anergic cells were generated in vitro by mixed culture of murine splenic cells from BALB/c and C3H/HeJ under the blockade of anti-CD154 and anti-CD80 monoclonal antibodies, and the in vitro activity of anergic cells were observed. The 3.0 Gy gamma-irradiated BALB/c mice received cardic allografts from C3H/HeJ, and anergic cells were intravenously injected immediately after transplantation. Recipient mice injected with anergic cells also received rapamycin therapy (1 mg/kg/day) for 14 days. On day 7 after transplantation, the subsets of peripheral blood T lymphocytes, the pathology of grafts and the infiltration of lymphocytes in grafts were analysed. Untreated gamma-irradiated animals showed a graft median survival time (MST) of 9 days. Animals injected with anergic cells only or receiving rapamycin therapy alone showed MST of 11 and 17 days, respectively. MST of allograft in mice treated with control cells plus rapamycin therapy was 9 days. Animals injected with anergic cells plus rapamycin therapy, but receiving third-party allografts (C57BL/6J), showed an MST of 15 days. However, anergic cell injection plus rapamycin therapy prolonged allograft survival significantly (MST 28 days, P<0.01). The rejection was mild and tissue architecture was preserved in recipient mice receiving anergic cell injection plus rapamycin therapy. Furthermore, anergic cells and rapamycin therapy decreased the percentage of peripheral blood CD4(+) and CD8(+) T cells (including CD25(+), CD152(+), CD154(+) and CD28(+) subsets) and greatly reduced the infiltrating lymphocytes in allografts (including CD3(+), CD4(+), CD8(+) and CD25(+) T cells). In conclusion, the treatment based on anergic cells' adoptive transfer plus rapamycin therapy demonstrated a significant prolongation of murine cardiac allograft survival in a donor antigen-specific manner. This therapeutic protocol alleviated allograft rejection to solid allograft in vivo.

Rapamycin Relieves Lentiviral Vector Transduction Resistance in Human and Mouse Hematopoietic Stem Cells.

Rapamycin Enhances CAR-T Control of HIV Replication and Reservoir Elimination in vivo.

CAR Gene Delivery by T-cell Targeted Lentiviral Vectors is Enhanced by Rapamycin Induced Reduction of Antiviral Mechanisms

Rapamycin Enhances Long-Term Hematopoietic Reconstitution Of Ex Vivo Expanded Mouse Hematopoietic Stem Cells By Inhibiting Senescence

Rap1 Deficiency-Provoked Paracrine Dysfunction Impairs Immunosuppressive Potency of Mesenchymal Stem Cells in Allograft Rejection of Heart Transplantation

PD-L1 Cellular Nanovesicles Carrying Rapamycin Inhibit Alloimmune Responses in Transplantation.

Lentiviral Vector Transduction of Hematopoietic Stem Cells That Mediate Long‐Term Reconstitution of Lethally Irradiated Mice

Rapamycin-resistant effector T-cell therapy

Subcutaneous nanotherapy repurposes the immunosuppressive mechanism of rapamycin to enhance allogeneic islet graft viability

Rapamycin promotes the expansion of CD4(+) Foxp3(+) regulatory T cells after liver transplantation.

Genomic Editing of the HIV-1 Coreceptor CCR5 in Adult Hematopoietic Stem and Progenitor Cells Using Zinc Finger Nucleases.

Rapamycin Treatment Alleviates Chronic GVHD-Induced Lupus Nephritis in Mice by Recovering IL-2 Production and Regulatory T Cells While Inhibiting Effector T Cells Activation

A Combination of Anergic Cells' Adoptive Transfer and Rapamycin Therapy Prolongs Cardiac Allograft Survival in Mice

Prevention of Lethal Acute GVHD with an Agonistic CD28 Antibody and Rapamycin.

Long‐term tracking of haematopoietic clonal dynamics and mutations in non‐human primate undergoing transplantation of lentivirally barcoded haematopoietic stem and progenitor cells

Therapeutic Effect of RANTES–KDEL on Inhibition of HIV-1 in CD34+ Human Hematopoietic Stem Cells (Hhsc)

Robust and efficient regulation of transgene expression in vivo by improved tetracycline-dependent lentiviral vectors

Limited Efficacy of Rapamycin Monotherapy in Vascularized Composite Allotransplantation.

Rapamycin Immunomodulation Utilizes Time-Dependent Alterations of Lymph Node Architecture, Leukocyte Trafficking, and Gut Microbiome

Crispr/Cas9-Mediated Ccr5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers Hiv-1 Resistance in Vivo

Immunomodulation of T Cell-Mediated Alloimmunity by Proximity to Endothelial Cells under the Mammalian Target of Rapamycin Blockade.